India’s drug pricing authority has given Abbott (NYSE:ABT) a year to pull its Xience Alpine drug-eluting stent from the market, according to an Indian Economic Times report.
The company approached India’s National Pharmaceutical Pricing Authority nearly a month ago looking to withdraw the device, citing price caps set on stents earlier this year.
Get the full story at our sister site, Drug Delivery Business News.
The post India gives Abbott a year to withdraw Xience Alpine stent appeared first on MassDevice.